Company profile
Abeona Therapeutics Inc.
NASDAQ: ABEO · Healthcare · Biotechnology
#692 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
69BFH 78DQ 54GM 63SS 82
v0.1 · 65/100 weight · provisional
↑ net margin, listing tenure · ↓ operating margin, filing timeliness
Methodology →Revenue TTM
$14.5M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$71.2M
Employees
226
as of 2026-08-12
Market cap
$421.8M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.8M$5.8M2025
Net income$71.2M$71.2M2025
Operating income-$89.4M-$89.4M2025
Total assets$219.6M$219.6M2025
Liabilities$60.4M$60.4M2025
Equity$159.2M$159.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY19
FY20
FY21
FY22
FY23
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License58%
Product42%
By geography
Not disclosed.
The read
What is Abeona Therapeutics Inc.’s revenue?
Abeona Therapeutics Inc. booked $5.8M in FY2025 revenue, growing 66% year over year — faster than most Healthcare companies we track, at a 1223.1% net margin.
Peers · Healthcare
Bloomios, Inc.——Australis Capital Inc.——Lancer Orthodontics, Inc.——MPX International Corp.——CarePayment Technologies, Inc.——Tristar Wellness Solutions Inc.——Neighbors
Oswego →Key facts
CEOVishwas Seshadri
SectorHealthcare
IndustryBiotechnology
HeadquartersCleveland, NY
ExchangeNASDAQ: ABEO
Employees226
IPO date1980-09-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.